VitroVo, Inc.
- CMO, CRO
- Biotech or pharma, therapeutic R&D
VitroVo is an emerging in vitro e-phys CRO based in Japan, specializing in advanced microelectrode array (MEA) assays powered by proprietary analytics and 20+ years of expertise. Our platform enables accurate prediction of in vivo outcomes including efficacy, MoA, and toxicity risk.
VitroVo’s MEA assays are both disease-agnostic (e.g., neurodegenerative, neurodevelopmental, pain) and modality-agnostic (e.g., small molecules, peptides, antibodies, ASOs, ADCs, viral vectors), allowing flexible adaptation to diverse research needs. Our multivariate analytics clearly identify which compound and dose restores a disease phenotype toward a healthy state. In addition, our AI models predict outcomes of novel compounds based on MEA data.
We support early discovery through safety assessment, including target ID/validation and lead optimization. Upon grant approval, we plan to launch Ca²⁺ imaging–based high-throughput electrophysiology assays and discovery collaborations using partner libraries.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}